phospho lyn (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
94
Structured Review
Cell Signaling Technology Inc
phospho lyn
Phospho Lyn, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hck/Phospho-LYN+(Tyr397)%2FLCK+(Tyr394)%2FHCK+(Tyr411)%2FBLK+(Tyr389)+Rabbit+mAb/pm41910156-264-31-34
Average 94 stars, based on 26 article reviews
Phospho Lyn, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hck/Phospho-LYN+(Tyr397)%2FLCK+(Tyr394)%2FHCK+(Tyr411)%2FBLK+(Tyr389)+Rabbit+mAb/pm41910156-264-31-34
Average 94 stars, based on 26 article reviews
phospho lyn - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
Western Blot:Article Title: A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas Article Snippet: Alexa Fluor 647-conjugated p -SYK( Tyr525/Tyr526 ), APC-Cy7-conjugated CD20 (BD Biosciences, San Jose, CA), and p -HCK( Tyr410 ) combined with DyLight 650-conjugated goat F(ab')2 anti-rabbit immunoglobulin G (IgG) antibody (Abcam, Cambridge, MA) were used for PhosFlow analysis. .. Western blotting was performed using antibodies to p -SYK( Tyr525/Tyr526 ) (R&D Systems), p -LYN (Tyr396) (GeneTex Inc), SYK, LYN, p -AKT( Ser473 ), AKT, p -ERK1/2( Thr202/Tyr204 ), ERK1/2, and Article Title: HCK induces macrophage activation to promote renal inflammation and fibrosis via suppression of autophagy Article Snippet: Cells were lysed with Cell Lysis Buffer II (ThermoFisher Scientific, # FNN0021) containing 1% NP-40, added protease inhibitor cocktail (Sigma, #P1860), L-isozymes of alkaline phosphatase inhibitor cocktail (Sigma, #P2850) and tyrosine and serine/threonine phosphatase inhibitors (Sigma, #P5726). .. Lysates were subjected to immunoblot analysis using the following antibodies: Article Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia. Article Snippet: To the Editor, MYD88 mutations (MYD88Mut) are present in several Bcell malignancies, including Waldenström macroglobulinaemia (WM) (95%–97%) and activated Bcell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (40%).. MYD88Mut triggers the formation of a ‘Myddosome’, which leads to the sequential activation of IRAK4/IRAK1, JAK2/STAT3 and HCK/BTK prosurvival signalling.1–5 The importance of BTK to MYD88Mut prosurvival signalling supported the development of both covalent and noncovalent BTK inhibitors and the approval of the covalent BTK inhibitors ibrutinib and zanubrutinib for the treatment of symptomatic WM.6,7 Despite the high level of activity of BTK inhibitors in WM, acquired resistance due to the emergence of BTKCys481Ser mutations is common.8 BTKCys481Ser mutations lead to the activation of ERK1/2 MAP kinases, which triggers interleukin (IL)6 and IL10 and propagates paracrinemediated BTKinhibitor resistance.9 Pacritinib is a multikinase inhibitor approved in the United States for the treatment of myelofibrosis.. Pacritinib blocks JAK2/STAT3, IRAK1 and cSRC, a highly homologous kinase to HCK.10,11 Since pacritinib targets multiple kinases implicated in MYD88Mut prosurvival signalling, we explored the repurposing of this U.S. Food and Drug Administration (FDA)approved therapeutic for the treatment of MYD88Mut WM. Article Title: HCK induces macrophage activation to promote renal inflammation and fibrosis via suppression of autophagy. Article Snippet: Cells were lysed with Cell Lysis Buffer II (ThermoFisher Scientific, # FNN0021) containing 1% NP-40, added protease inhibitor cocktail (Sigma, #P1860), L-isozymes of alkaline phosphatase inhibitor cocktail (Sigma, #P2850) and tyrosine and serine/threonine phosphatase inhibitors (Sigma,#P5726). .. Lysateswere subjected to immunoblot analysis using the following antibodies: Cell-Signaling:Article Title: A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas Article Snippet: Alexa Fluor 647-conjugated p -SYK( Tyr525/Tyr526 ), APC-Cy7-conjugated CD20 (BD Biosciences, San Jose, CA), and p -HCK( Tyr410 ) combined with DyLight 650-conjugated goat F(ab')2 anti-rabbit immunoglobulin G (IgG) antibody (Abcam, Cambridge, MA) were used for PhosFlow analysis. .. Western blotting was performed using antibodies to p -SYK( Tyr525/Tyr526 ) (R&D Systems), p -LYN (Tyr396) (GeneTex Inc), SYK, LYN, p -AKT( Ser473 ), AKT, p -ERK1/2( Thr202/Tyr204 ), ERK1/2, and Control:Article Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia. Article Snippet: To the Editor, MYD88 mutations (MYD88Mut) are present in several Bcell malignancies, including Waldenström macroglobulinaemia (WM) (95%–97%) and activated Bcell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (40%).. MYD88Mut triggers the formation of a ‘Myddosome’, which leads to the sequential activation of IRAK4/IRAK1, JAK2/STAT3 and HCK/BTK prosurvival signalling.1–5 The importance of BTK to MYD88Mut prosurvival signalling supported the development of both covalent and noncovalent BTK inhibitors and the approval of the covalent BTK inhibitors ibrutinib and zanubrutinib for the treatment of symptomatic WM.6,7 Despite the high level of activity of BTK inhibitors in WM, acquired resistance due to the emergence of BTKCys481Ser mutations is common.8 BTKCys481Ser mutations lead to the activation of ERK1/2 MAP kinases, which triggers interleukin (IL)6 and IL10 and propagates paracrinemediated BTKinhibitor resistance.9 Pacritinib is a multikinase inhibitor approved in the United States for the treatment of myelofibrosis.. Pacritinib blocks JAK2/STAT3, IRAK1 and cSRC, a highly homologous kinase to HCK.10,11 Since pacritinib targets multiple kinases implicated in MYD88Mut prosurvival signalling, we explored the repurposing of this U.S. Food and Drug Administration (FDA)approved therapeutic for the treatment of MYD88Mut WM. Staining:Article Title: SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy. Article Snippet: Natural killer (NK) cells express activating receptors that signal through ITAM (immunoreceptor tyrosine-based activation motif)-bearing adapter proteins.. The phosphorylation of each ITAM creates binding sites for SYK and ZAP70 protein tyrosine kinases to propagate downstream signaling including the induction of Ca influx.. While all immature and mature human NK cells coexpress SYK and ZAP70, clonally driven memory or adaptive NK cells can methylate SYK genes, and signaling is mediated exclusively using ZAP70. other:Article Title: Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy Article Snippet: Images were collected using the Vectra 3.0 Automated Quantitative Pathology Imaging System. |